Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a trial of NS101 in primary progressive aphasia variant frontotemporal dementia
KCT0011077Phase 2Active, not recruiting
- Sponsor
- Neuracle Science
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of NS101 in frontotemporal dementia (FTD), sponsored by Neuracle Science. Started Dec 2025; status: active, not recruiting.
02
Drugs
NS101
03
Conditions
frontotemporal dementia (FTD)
Beyond the preview
Go deeper on KCT0011077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011077.